LianBio 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
80 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Truseltiq (infigratinib) / BridgeBio, Pfizer, Xediton Pharma
PROOF 301, NCT03773302 / 2018-004004-19: Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations

Checkmark BridgeBio terminated ongoing phase 3 clinical trial for treating 1L cholangiocarcinoma as a result of withdrawal of NDA
Oct 2022 - Oct 2022: BridgeBio terminated ongoing phase 3 clinical trial for treating 1L cholangiocarcinoma as a result of withdrawal of NDA
Checkmark Fast track and orphan drug designation for the treatment of cholangiocarcinoma
Jan 2020 - Jan 2020: Fast track and orphan drug designation for the treatment of cholangiocarcinoma
Terminated
3
48
Europe, Canada, US, RoW
BGJ398, Infigratinib, Gemcitabine, Cisplatin
QED Therapeutics, Inc., Helsinn Healthcare SA
Advanced Cholangiocarcinoma, FGFR2 Gene Mutation
03/23
03/23
PROPEL3, NCT06164951: A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia

Active, not recruiting
3
110
Europe, Canada, US, RoW
Infigratinib 0.25 mg/kg/day, Placebo Comparator 0.25 mg/kg/day
QED Therapeutics, Inc.
Achondroplasia
12/25
04/26
NCT06926491: Evaluate the Efficacy and Safety of KK8398 in Patients With Achondroplasia（AOBA Study）

Recruiting
3
6
Japan
KK8398
Kyowa Kirin Co., Ltd.
Achondroplasia
05/29
05/31
HCH, NCT06873035: An Interventional Study of Infigratinib in Children With Hypochondroplasia

Enrolling by invitation
2/3
24
Europe, Canada, US, RoW
infigratinib 0.128 mg/kg/day, infigratinib 0.25 mg/kg/day
QED Therapeutics, Inc.
Hypochondroplasia
01/27
01/27
NCT05019794: Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations

Checkmark NMPA cleared CTA to conduct the Phase 2a trial for metastatic gastric cancer or GE junction adenocarcinoma with FGFR2 gene amplification
Dec 2020 - Dec 2020: NMPA cleared CTA to conduct the Phase 2a trial for metastatic gastric cancer or GE junction adenocarcinoma with FGFR2 gene amplification
Recruiting
2a
80
RoW
Infigratinib, BGJ398
LianBio LLC
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Solid Tumor
12/22
12/23
2021-001855-15: A study to evaluate long-term Infigratinib in children with Achondroplasia Un estudio para evaluar Infigratinib a largo plazo en niños con acondroplasia

Not yet recruiting
2
280
Europe
Infigratinib, BGJ398 (also known as BBP-831), Tablet
QED Therapeutics, Inc., QED Therapeutics, Inc.
Achondroplasia in Children Acondroplasia en niños, Disproportionate short stature with rhizomelia (shortened proximal limbs). Estatura desproporcionádamente corta con rizomelia (miembros proximales acortados), Diseases [C] - Musculoskeletal Diseases [C05]
 
 
LOGIC-2, NCT02159066 / 2013-004552-38: LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma

Checkmark Clinical activity and tolerability data from LOGIC-2 trial of binimetinib, encorafenib with a third agent (LEE011, BKM120, BFJ398 or INC280) combination for BRAF melanoma at ECC 2015
Sep 2015 - Sep 2015: Clinical activity and tolerability data from LOGIC-2 trial of binimetinib, encorafenib with a third agent (LEE011, BKM120, BFJ398 or INC280) combination for BRAF melanoma at ECC 2015
Checkmark From LOGIC-2 trial for advanced BRAF V600 melanoma at ECC 2015
Sep 2015 - Sep 2015: From LOGIC-2 trial for advanced BRAF V600 melanoma at ECC 2015
Completed
2
158
Europe, Canada, US, RoW
LGX818, MEK162, LEE011, BGJ398, BKM120, INC280
Pfizer
Melanoma
01/23
01/23
PROPEL 2, NCT04265651 / 2019-002954-21: Study of Infigratinib in Children with Achondroplasia

Completed
2
84
Europe, Canada, US, RoW
Infigratinib 0.016 mg/kg, Infigratinib 0.032 mg/kg, Infigratinib 0.064 mg/kg, Infigratinib 0.128 mg/kg, Infigratinib 0.25 mg/kg
QED Therapeutics, Inc.
Achondroplasia
10/24
10/24
NCT06206278: Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma

Terminated
2
6
RoW
Infigratinib, BGJ398, BBP-831
LianBio LLC
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
05/24
05/24
NCT04233567: Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations

Checkmark Decision to withdraw NDA for Truseltiq which was approved for adult patients with unresectable locally advanced/metastatic 2L cholangiocarcinoma with FGFR2 fusion or other rearrangement
Oct 2022 - Oct 2022: Decision to withdraw NDA for Truseltiq which was approved for adult patients with unresectable locally advanced/metastatic 2L cholangiocarcinoma with FGFR2 fusion or other rearrangement
Checkmark Health Canada approved for the treatment of adults unresectable locally advanced or metastatic 2L cholangiocarcinoma
Sep 2021 - Sep 2021: Health Canada approved for the treatment of adults unresectable locally advanced or metastatic 2L cholangiocarcinoma
Checkmark Approved for previously-treated locally advanced or metastatic cholangiocarcinoma harboring an FGFR2 fusion or rearrangement
More
Active, not recruiting
2
17
US
Infigratinib, 3-(2,6-Dichloro-3,5-dimethoxyphenyl)-1-(6-((4-(4-ethylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)-1-methylurea, BGJ-398, BGJ398
Sameek Roychowdhury
Advanced Malignant Solid Neoplasm, Cholangiocarcinoma, Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
12/23
12/25
NCT05514912: Preoperative Nab-paclitaxel, Cisplatin, and Gemcitabine Chemotherapy With or Without Infigratinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, The OPTIC Trial

Withdrawn
2
40
NA
Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, FF 10832, FF-10832, FF10832, Gemcitabine HCI, Gemzar, LY-188011, LY188011, Infigratinib Phosphate, N'-(2,6-Dichloro-3,5-dimethoxyphenyl)-N-(6-(4-(4-ethylpiperazin-1-yl)anilino)pyrimidin-4-yl)-N-methylurea Phosphate (1:1), Truseltiq, Nab-paclitaxel, ABI 007, ABI-007, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, Nanoparticle Albumin-bound Paclitaxel, Nanoparticle Paclitaxel, Paclitaxel Albumin, paclitaxel albumin-stabilized nanoparticle formulation, Protein-bound Paclitaxel
Emory University, National Cancer Institute (NCI)
Resectable Intrahepatic Cholangiocarcinoma, Stage 0 Intrahepatic Cholangiocarcinoma AJCC v8, Stage I Intrahepatic Cholangiocarcinoma AJCC v8, Stage II Intrahepatic Cholangiocarcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8
06/27
06/27
NCT05145010 / 2021-001855-15: Extension Study of Infigratinib in Children With Achondroplasia (ACH)

Enrolling by invitation
2
300
Europe, Canada, US, RoW
Infigratinib
QED Therapeutics, Inc., QED Therapeutics, Inc.
Achondroplasia
12/31
02/32
NEWEL, NCT05222165 / 2021-005614-34: Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations

Withdrawn
1b/2
51
Europe, Canada, US
Infigratinib, BGJ398
Helsinn Healthcare SA, Labcorp Drug Development Inc
Advanced Solid Tumor, CNS Tumor, Recurrent WHO Grade II Glioma
12/22
12/22
2021-005614-34: Study of Infigratinib in Subjects with Advanced Solid and CNS Tumorsor Recurrent or Progressive Low-Grade Glioma with Selected FGFR1-3 Alterations

Not yet recruiting
1/2
51
Europe
Infigratinib hard gelatin sprinkle capsules 18 mg, Infigratinib hard gelatin sprinkle capsules 25 mg, Infigratinib hard gelatin locking capsules 75 mg, BGJ398, BBP-831, Capsule, hard, TRUSELTIQ (infigratinib hard gelatin locking capsules 25 mg), TRUSELTIQ (infigratinib hard gelatin locking capsules 100 mg)
Helsinn Healthcare SA, Helsinn Healthcare SA
Advanced solid and CNS tumors with selected FGFR1-3 mutations or fusions/rearrangements, inclusive of recurrent or progressive low-grade glioma (LGG) with selected FGFR1-3 mutations or fusions/rearrangements., Advanced solid and central nervous system tumors (brain tumors) that is coming back after treatment (recurrent) or getting worse (progressive)., Diseases [C] - Nervous System Diseases [C10]
 
 
NCT04228042: Infigratinib Before Surgery for the Treatment of Upper Tract Urothelial Cancer

Terminated
1/2
15
US
Infigratinib, 3-(2,6-Dichloro-3,5-dimethoxyphenyl)-1-(6-((4-(4-ethylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)-1-methylurea, BGJ-398, BGJ398, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Surgical Procedure, Operation, Surgery, Surgical, Surgical Intervention, Surgical Interventions, Surgical Procedures, Type of Surgery
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Renal Pelvis and Ureter Urothelial Carcinoma
04/24
04/24
NCT04424966: Infigratinib in Recurrent High-Grade Glioma Patients

Terminated
1
7
US
Infigratinib
Nader Sanai, Ivy Brain Tumor Center, Barrow Neurological Institute, QED Therapeutics
Glioma, Glioblastoma, GBM
04/23
04/23
NCT05510427: Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification

Withdrawn
1
28
NA
Infigratinib, Atezolizumab, Bevacizumab
M.D. Anderson Cancer Center, Helsinn Healthcare SA
Cholangiocarcinoma, Liver Cancer
08/23
08/23
NCT02657486: BGJ398 in Non-Muscle-Invasive Urothelial Carcinoma of the Bladder

Active, not recruiting
N/A
4
US
BGJ398
Memorial Sloan Kettering Cancer Center
Bladder Cancer, Non-Muscle-Invasive Urothelial Carcinoma
01/26
01/26
Hensify (crystalline hafnium oxide) / Nanobiotix, J&J
2021-002163-22: NBTXR3 with or without cetuximab in Locally Advanced Head & Neck Squamous Cell Carcinoma (LA-HNSCC)

Not yet recruiting
3
500
Europe, RoW
Cetuximab, [NA], [NBTXR3], Solution for infusion, Erbitux, 5 mg/mL, 20 mL vials
Nanobiotix SA, NANOBIOTIX SA, NANOBIOTIX, Nanobiotix SA
Locally Advanced Head & Neck Squamous Cell Carcinoma, The most common type of head and neck cancer is called squamous cell carcinoma coming from the membrane lining the mouth, and the parts of the digestive and respiratory tubes of the neck., Diseases [C] - Cancer [C04]
 
 
NANORAY-312, NCT04892173 / 2021-002163-22: JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

Recruiting
3
500
Europe, Japan, US, RoW
JNJ-90301900 (NBTXR3), Functionalized hafnium oxide nanoparticles, NBTXR3, Cetuximab, Erbitux, Radiation Therapy
Johnson & Johnson Enterprise Innovation Inc., Nanobiotix SA
Locally Advanced Head and Neck Squamous Cell Carcinoma, Aged
06/26
06/27
CONVERGE, NCT06667908: A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

Recruiting
2
130
US, RoW
JNJ-90301900, Durvalumab, Concurrent Chemo/Radiation Therapy (cCRT), Concurrent Chemo/Radiation Therapy (cCRT): Carboplatin, Concurrent Chemo/Radiation Therapy (cCRT): Paclitaxel
Johnson & Johnson Enterprise Innovation Inc.
Carcinoma, Non-Small-Cell Lung
12/28
12/28
NCT04862455: NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Cancer

Active, not recruiting
2
14
US
Hafnium Oxide-containing Nanoparticles NBTXR3, NBTXR3, Hypofractionated Radiation Therapy, Hypofractionated Radiotherapy, hypofractionation, Radiation, Hypofractionated, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Stereotactic Body Radiation Therapy, SABR, SBRT, Stereotactic Ablative Body Radiation Therapy
M.D. Anderson Cancer Center
Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
09/26
09/26
NCT05039632: Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies

Recruiting
1/2
40
US
Hafnium Oxide-containing Nanoparticles NBTXR3, NBTXR3, Radiation Therapy, Cancer Radiotherapy, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Liver, Metastatic Malignant Neoplasm in the Lung, Metastatic Malignant Solid Neoplasm
02/26
02/26
NBTXR3-102, NCT01946867: NBTXR3 and Radiation Therapy in Treating Patients With Locally Advanced SCC of the Oral Cavity or Oropharynx

Active, not recruiting
1
75
Europe
NBTXR3 activated by IMRT
Nanobiotix
Head and Neck Cancer
02/23
02/23
Study 1100, NCT03589339: NBTXR3 Activated by Radiotherapy for Patients with Advanced Cancers Treated with an Anti-PD-1 Therapy

Recruiting
1
145
US
NBTXR3, SABR, Stereotaxic Ablative Radiotherapy, Stereotaxic Body Radiation Therapy, Nivolumab, Opdivo, Pembrolizumab, Keytruda
Nanobiotix
Radiotherapy, Immunotherapy, Microsatellite Instability-High Solid Malignant Tumour, Metastasis from Malignant Tumor of Liver, Squamous Cell Carcinoma of Head and Neck, Metastasis from Malignant Tumor of Cervix, Metastatic Renal Cell Carcinoma, Metastasis from Malignant Melanoma of Skin (disorder), Metastatic Triple-Negative Breast Carcinoma, Metastatic NSCLC, Metastasis from Malignant Tumor of Bladder (Disorder)
04/27
05/28
NCT04505267: NBTXR3 and Radiation Therapy for the Treatment of Inoperable Recurrent Non-small Cell Lung Cancer

Recruiting
1
24
US
Hafnium Oxide-containing Nanoparticles NBTXR3, NBTXR3, Radiation Therapy, Cancer Radiotherapy, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Recurrent Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma
03/26
03/26
NCT04615013: NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer

Recruiting
1
24
US
Capecitabine, Ro 09-1978/000, Xeloda, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Docetaxel, Docecad, RP56976, Taxotere, Taxotere Injection Concentrate, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Hafnium Oxide-containing Nanoparticles NBTXR3, NBTXR3, Intensity-Modulated Radiation Therapy, IMRT, Intensity Modulated RT, Intensity-Modulated Radiotherapy, Radiation, Intensity-Modulated Radiotherapy, Leucovorin, Folinic acid, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Cervical Esophagus Adenocarcinoma, Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Gastroesophageal Junction Adenocarcinoma, Pathologic Stage II Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage III Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8, Thoracic Esophagus Adenocarcinoma
10/25
10/25
NCI-2020-03731, NCT04484909: NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer

Recruiting
1
24
US
Hafnium Oxide-containing Nanoparticles NBTXR3, NBTXR3, Radiation Therapy, Cancer Radiotherapy, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8
12/26
12/26
Camzyos (mavacamten) / BMS
NCT07004972: A Study of Mavacamten in Adults With Obstructive Hypertrophic Cardiomyopathy in India (ROVER)

Not yet recruiting
4
50
RoW
Mavacamten, BMS-986427
Bristol-Myers Squibb
Symptomatic Obstructive Hypertrophic Cardiomyopathy
12/27
12/27
MEMENTO, NCT06112743: A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Recruiting
4
85
Europe, Canada, US, RoW
Mavacamten
Bristol-Myers Squibb
Cardiomyopathy, Hypertrophic
09/26
09/26
VALOR-HCM, NCT04349072: A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy

Completed
3
112
US
Mavacamten, Placebo
Bristol-Myers Squibb
HOCM, Hypertrophic Obstructive Cardiomyopathy
02/22
05/24
2021-005329-26: A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with Cardiomyopathy

Ongoing
3
420
Europe
Mavacamten, MYK-461, Capsule, hard
Myokardia, Inc., Myokardia, Inc.
Symptomatic Nonobstructive Hypertrophic Cardiomyopathy, Symptomatic hardening of the left ventricle., Diseases [C] - Cardiovascular Diseases [C14]
 
 
EXPLORER-CN, NCT05174416: A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCM

Completed
3
81
RoW
Mavacamten, MYK-461, BMS-986327, Placebo
LianBio LLC
Obstructive Hypertrophic Cardiomyopathy
03/23
07/24
HORIZON-HCM, NCT05414175: A Study of Mavacamten in Obstructive Hypertrophic Cardiomyopathy

Active, not recruiting
3
38
Japan
Mavacamten, BMS-986427, MYK-461
Bristol-Myers Squibb
Cardiomyopathy, Hypertrophic Obstructive
11/23
03/26
SCOUT-HCM, NCT06253221: A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Active, not recruiting
3
40
Europe, Canada, US, RoW
Mavacamten, BMS-986427, Placebo
Bristol-Myers Squibb
Cardiomyopathy, Hypertrophic
02/28
03/31
ODYSSEY_HCM, NCT05582395 / 2021-005329-26: A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy

Active, not recruiting
3
580
Europe, Canada, Japan, US, RoW
Mavacamten, BMS-986427, MYK-461, Placebo
Bristol-Myers Squibb
Cardiomyopathy, Hypertrophic
03/25
06/29
NCT03723655 / 2018-004039-64: A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM

Active, not recruiting
2/3
282
Europe, US, RoW
mavacamten, MYK-461
Bristol-Myers Squibb
Hypertrophic Cardiomyopathy, Obstructive Hypertrophic Cardiomyopathy, Non-obstructive Hypertrophic Cardiomyopathy
01/26
01/26
PIONEER-OLE, NCT03496168: Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in PIONEER

Completed
2
13
US
mavacamten, MYK-461
Bristol-Myers Squibb
Hypertrophic Cardiomyopathy
11/23
11/23
EMBARK-HFpEF, NCT04766892: A Study of Mavacamten in Participants With HFpEF and Elevation of NT-proBNP With or Without Elevation of cTnT

Completed
2
30
Canada, US
mavacamten
Bristol-Myers Squibb
Heart Failure With Preserved Ejection Fraction
02/24
02/24
NCT05658146: A Study to Assess the Effects on the Single-Dose Drug Levels of Mavacamten in Healthy Participants

Completed
1
95
US
Mavacamten Capsule 1, BMS-986427, MYK-461, Mavacamten Capsule 2, Mavacamten Capsule 3
Bristol-Myers Squibb
Healthy Participants
07/23
07/23
NCT05719805: A Study to Evaluate the Effects of Mavacamten in Healthy Participants

Completed
1
84
US
Mavacamten, MYK-461
Bristol-Myers Squibb
Healthy Participants
07/23
07/23
NCT06211179: A Study to Assess the Relative Bioavailability of 5 mg Mavacamten Opened Capsule Administered Via Nasogastric Tube Compared to Intact Oral 5 mg Mavacamten in Healthy Participants

Completed
1
34
US
Treatment A: Mavacamten intact oral capsule, Treatment B: Mavacamten open capsule in suspension, Treatment C: Mavacamten open capsule in suspension administered via nasogastric tube (NGT)
Bristol-Myers Squibb
Healthy Volunteers
06/24
06/24
COLLIGO-HCM, NCT06372457: A Multinational Observational Study of the Real-World Effectiveness of Mavacamten Among Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

Active, not recruiting
N/A
500
US
Approved Hypertrophic Cardiomyopathy drug treatments, Mavacamten
Bristol-Myers Squibb
Hypertrophic Cardiomyopathy (HCM)
03/25
06/25
NCT06549608: A Retrospective Cohort Study of Mavacamten Patient Support Program in Canada

Active, not recruiting
N/A
685
Canada
Mavacamten
Bristol-Myers Squibb
Hypertrophic Cardiomyopathy
05/24
04/25
COMPASS-HCM, NCT06551129: Real-world Patient Reported Outcomes Among Patients Treated With Camzyos

Recruiting
N/A
118
US
Mavacamten
Bristol-Myers Squibb
Obstructive Hypertrophic Cardiomyopathy
12/26
06/27
MAVEN, NCT06338202: Real-World Effectiveness of Mavacamten in Canada

Recruiting
N/A
100
Canada
Mavacamten
Bristol-Myers Squibb
Obstructive Hypertrophic Cardiomyopathy (oHCM)
11/24
11/24
NCT06146660: A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Recruiting
N/A
600
RoW
Mavacamten
Bristol-Myers Squibb
Obstructive Hypertrophic Cardiomyopathy
11/26
11/26
NCT06856265: Efficacy of Mavacamten Combined With Radiofrequency Ablation in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Not yet recruiting
N/A
40
NA
radiofrequency ablation, Mavacamten
Shanghai Chest Hospital
Obstructive Hypertrophic Cardiomyopathy, Mavacamten, Radiofrequency Ablation
12/25
12/25
NCT06947590: Efficacy of Mavacamten in Patients With Symptomatic Latent Obstructive Hypertrophic Cardiomyopathy

Active, not recruiting
N/A
78
RoW
mavacamten
Xu Liu
HCM - Hypertrophic Cardiomyopathy, Mavacamten
02/26
02/26
MavaPET, NCT06023186: Effect of Mavacamten Treatment on Coronary Flow Reserve in oHCM

Recruiting
N/A
20
US
mavacamten, Camzyos
Michael Ayers, Bristol-Myers Squibb
Obstructive Hypertrophic Cardiomyopathy
08/26
09/26
NCT05939700: Mavacamten Pregnancy Surveillance Program

Recruiting
N/A
20
US
Mavacamten
Bristol-Myers Squibb
Breastfeeding, Hypertrophic Cardiomyopathy, Pregnancy Related
04/27
04/27
DISCOVER-HCM, NCT05489705: A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)

Recruiting
N/A
1600
Europe, US
Mavacamten, Non-mavacamten symptomatic oHCM therapy
Bristol-Myers Squibb
Obstructive Hypertrophic Cardiomyopathy
08/29
08/29
omilancor (BT-11) / LianBio, NImmune Biopharma
ACTRN12618001210268: A Randomized, Placebo-Controlled, Sequential Single and Multiple Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral BT-11 in Healthy Adult Male and Female Volunteers

Recruiting
1
70
 
Landos Biopharma Australia Pty Ltd, Landos Biopharma Australia Pty. Ltd.
Inflammatory Bowel Disease, Ulcerative colitis, Crohn's Disease
 
 
sisunatovir (PF-07923568) / LianBio
NCT06079320: A Study to Learn About the Study Medicine Sisunatovir in Adults With Respiratory Syncytial Virus (RSV) Infection

Terminated
2/3
16
Japan, US, RoW
Sisunatovir, Placebo
Pfizer
Respiratory Syncytial Virus Infection
09/24
09/24
2017-001282-24: A clinical trial of RV521 in healthy volunteers

Not yet recruiting
2
66
Europe
RV521 50mg, RV521 100mg, RV521, 200mg, RV521, Capsule
ReViral Ltd, ReViral Ltd
Respiratory Syncytial Virus Infection, RSV is a common virus that can cause severe chest infections in small children, adults with heart, lung and immune system conditions and elderly people., Diseases [C] - Virus Diseases [C02]
 
 
2019-003746-33: Study of RV521 for the treatment of adults who have received a blood cell transplant and that have a respiratory infection caused by the virus RSV

Not yet recruiting
2
200
Europe
RV521, Capsule
ReViral Ltd., ReViral
Symptomatic RSV infection (upper airway involvement only) in subjects who have undergone HCT transplantation within 1 year of Randomization and who are moderately to severely immunocompromised., respiratory infection, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
REVIRAL 1, NCT04225897: A Study to Learn About the Effects of Sisunatovir in Infants With Respiratory Syncytial Virus Lower Respiratory Tract Infection.

Terminated
2
51
Europe, Canada, RoW
RV521, sisunatovir, Placebo
Pfizer
Respiratory Syncytial Virus (RSV), Lower Resp Tract Infection
12/22
12/22
2018-001010-15: A phase 2a Study in Infants with RSV lower respiratory tract infection, to evaluate the safety, tolerability, pharmacokinetics and antiviral effect of RV521.

Not yet recruiting
2
184
Europe
Sisunatovir, RV521, Powder for oral solution
ReViral Ltd., ReViral Ltd.
Respiratory Syncytial Virus Infection, Respiratory Syncytial Virus Infection, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
NCT05873764: A Study to Learn About Effect of Sisunatovir in Healthy Adult Male Participants

Completed
1
9
US
200 mg RV521/78 µCi [ 14C]-RV521.
Pfizer
Respiratory Syncytial Virus Infections
07/22
07/22
NCT05712460: A Study to Assess the Safety, Effects and Palatability of Sisunatovir in Healthy Adult Participants

Completed
1
12
Europe
sisunatovir, Placebo
Pfizer
Respiratory Syncytial Viruses
04/23
04/23
NCT06003829: A Study to Learn About the Tastes of Different Suspensions With the Study Medicine (PF-07923568) in Healthy Adult Participants.

Completed
1
12
Europe
Sinsunatovir, Bitrex
Pfizer
Healthy
09/23
09/23
NCT05878522: A Study to Investigate the Effects of Sisunatovir on QTc Interval in Healthy Adult Participants.

Completed
1
43
US
sisunatovir, PF-07923568, placebo, moxifloxacin
Pfizer
Healthy
10/23
10/23
NCT05994963: A Study to Compare Different Preparations of Sisunatovir in Healthy Adult Participants.

Completed
1
25
Europe
sisunatovir, PF-07923568, RV521
Pfizer
Healthy
02/24
02/24
NCT05857644: A Study to Compare How the Study Medicine (PF-07923568) is Processed in Participants With Different Levels of Loss of Liver Function to Healthy Participants.

Completed
1
28
US
PF-07923568, Sisunatovir
Pfizer
Liver Diseases, Hepatic Impairment
02/24
02/24
NCT06105983: A Study to Learn How a Medicine That Reduces Stomach Acid Affects the Level of Sisunatovir in the Blood of Healthy Adults.

Completed
1
40
Europe
Sisunatovir, Rabeprazole 40 mg, Sisunatovir suspension, Rabeprazole 20 mg
Pfizer
Healthy
07/24
07/24
NCT05987072: A Study to Learn How the Study Medicine Called Sisunatovir is Tolerated and Acts in the Bodies of Chinese Healthy Adults.

Completed
1
12
RoW
Sisunatovir
Pfizer
Respiratory Syncytial Virus Infection
12/23
12/23
NCT06037031: A Study to Learn How the Body Processes the Study Medicine Called PF-07923568 in People With Loss of Kidney Function

Completed
1
16
US
Drug: PF-07923568, Sisunatovir
Pfizer
Renal Impairment
07/24
07/24
NCT06102174: A Study to Learn About the Amount of the Study Medicine (Sisunatovir) in Blood and Its Safety in Infants and Children With Pneumonia Caused by RSV

Terminated
1
10
Japan, US, RoW
Placebo, Active, PF-07923568, RV521
Pfizer
Respiratory Syncytial Virus Infections
09/24
09/24
amelenodor (ABBV-113) / AbbVie
NCT05785715: Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis

Hourglass Oct 2024 - Dec 2024 : Topline data from trial for moderate to severe ulcerative colitis
Terminated
2
81
Europe, US
NX-13 250mg, NX-13 750mg, NX-13 Placebo
AbbVie
Ulcerative Colitis
05/25
05/25
Xdemvy (lotilaner ophthalmic) / Tarsus Pharma
Ariel, NCT06182358: Impact of XDEMVY® on Demodex Blepharitis in Soft Contact Lens Wearers

Completed
4
145
US
Lotilaner ophthalmic solution, 0.25%, Vehicle control
Tarsus Pharmaceuticals, Inc.
Demodex Blepharitis
01/25
01/25
NCT05629390: Trial to Evaluate the Efficacy and Safety of TP-03, LIBRA Study

Completed
3
163
RoW
Lotilaner, TP-03, S-Misoxam, Vehicle Control
LianBio LLC
Blepharitis
09/23
04/24
Ersa, NCT05454956: Pilot Study Comparing the Safety and Efficacy of Two Dosing Regimens of TP-03 for the Treatment of MGD

Completed
2
40
US
TP-03, TP-03 Vehicle
Tarsus Pharmaceuticals, Inc.
Meibomian Gland Dysfunction, Blepharitis, Demodex Infestation
05/23
05/23
Rhea, NCT06054217: Effect of an Exploratory Vehicle on Meibomian Gland Dysfunction in Patients With Demodex

Active, not recruiting
2
36
US
Vehicle of TP-03, Exploratory Vehicle
Tarsus Pharmaceuticals, Inc.
Meibomian Gland Dysfunction, Demodex Infestation of Eyelid, Blepharitis, Demodectic Blepharitis
06/24
06/24
NCT05138861: A Six Week Pharmacokinetic Study of TP-03 in Healthy Subjects

Completed
1
24
Canada
TP-03 (Lotilaner Ophthalmic Solution), 0.25%
Tarsus Pharmaceuticals, Inc.
Healthy
09/21
09/21
BMS-986466 / BMS
NCT06024174: A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors

Terminated
1/2
5
Europe, US, RoW
BMS-986466, BBP-398, IACS-15509, Adagrasib, MRTX849, KRAZATI®, Cetuximab, Erbitux®
Bristol-Myers Squibb
Advanced Solid Tumors
05/24
05/24
NCT04528836: First-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients With Advanced Solid Tumors

Terminated
1
72
US
BBP-398 (Formerly known as IACS-15509)
Navire Pharma Inc., a BridgeBio company
Tumor, Solid
03/24
07/24
NCT05621525: Phase I Study of the BBP-398 in Patients With Advance Solid Tumors

Terminated
1
7
RoW
BBP-398, IACS-15509
LianBio LLC
Advanced Solid Tumor, Advanced or Metastatic Non-small Cell Lung Cancer
03/24
03/24
Argonaut, NCT05480865: SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation

Terminated
1
28
Europe, RoW
BBP-398, sotorasib
Navire Pharma Inc., a BridgeBio company, Amgen
Solid Tumor, Adult, Metastatic Solid Tumor, Metastatic NSCLC, Non Small Cell Lung Cancer
08/24
08/24
NCT05375084: SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation

Terminated
1
21
US
BBP-398 with nivolumab
Navire Pharma Inc., a BridgeBio company, Bristol-Myers Squibb
Non Small Cell Lung Cancer, Solid Tumor
04/24
07/24
NCT06032936: BBP-398 in Combination With Osimertinib in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutations

Terminated
1
4
RoW
BBP-398, IACS-15509, osimertinib
LianBio LLC
NSCLC
03/24
03/24
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Truseltiq (infigratinib) / BridgeBio, Pfizer, Xediton Pharma
PROOF 301, NCT03773302 / 2018-004004-19: Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations

Checkmark BridgeBio terminated ongoing phase 3 clinical trial for treating 1L cholangiocarcinoma as a result of withdrawal of NDA
Oct 2022 - Oct 2022: BridgeBio terminated ongoing phase 3 clinical trial for treating 1L cholangiocarcinoma as a result of withdrawal of NDA
Checkmark Fast track and orphan drug designation for the treatment of cholangiocarcinoma
Jan 2020 - Jan 2020: Fast track and orphan drug designation for the treatment of cholangiocarcinoma
Terminated
3
48
Europe, Canada, US, RoW
BGJ398, Infigratinib, Gemcitabine, Cisplatin
QED Therapeutics, Inc., Helsinn Healthcare SA
Advanced Cholangiocarcinoma, FGFR2 Gene Mutation
03/23
03/23
PROPEL3, NCT06164951: A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia

Active, not recruiting
3
110
Europe, Canada, US, RoW
Infigratinib 0.25 mg/kg/day, Placebo Comparator 0.25 mg/kg/day
QED Therapeutics, Inc.
Achondroplasia
12/25
04/26
NCT06926491: Evaluate the Efficacy and Safety of KK8398 in Patients With Achondroplasia（AOBA Study）

Recruiting
3
6
Japan
KK8398
Kyowa Kirin Co., Ltd.
Achondroplasia
05/29
05/31
HCH, NCT06873035: An Interventional Study of Infigratinib in Children With Hypochondroplasia

Enrolling by invitation
2/3
24
Europe, Canada, US, RoW
infigratinib 0.128 mg/kg/day, infigratinib 0.25 mg/kg/day
QED Therapeutics, Inc.
Hypochondroplasia
01/27
01/27
NCT05019794: Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations

Checkmark NMPA cleared CTA to conduct the Phase 2a trial for metastatic gastric cancer or GE junction adenocarcinoma with FGFR2 gene amplification
Dec 2020 - Dec 2020: NMPA cleared CTA to conduct the Phase 2a trial for metastatic gastric cancer or GE junction adenocarcinoma with FGFR2 gene amplification
Recruiting
2a
80
RoW
Infigratinib, BGJ398
LianBio LLC
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Solid Tumor
12/22
12/23
2021-001855-15: A study to evaluate long-term Infigratinib in children with Achondroplasia Un estudio para evaluar Infigratinib a largo plazo en niños con acondroplasia

Not yet recruiting
2
280
Europe
Infigratinib, BGJ398 (also known as BBP-831), Tablet
QED Therapeutics, Inc., QED Therapeutics, Inc.
Achondroplasia in Children Acondroplasia en niños, Disproportionate short stature with rhizomelia (shortened proximal limbs). Estatura desproporcionádamente corta con rizomelia (miembros proximales acortados), Diseases [C] - Musculoskeletal Diseases [C05]
 
 
LOGIC-2, NCT02159066 / 2013-004552-38: LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma

Checkmark Clinical activity and tolerability data from LOGIC-2 trial of binimetinib, encorafenib with a third agent (LEE011, BKM120, BFJ398 or INC280) combination for BRAF melanoma at ECC 2015
Sep 2015 - Sep 2015: Clinical activity and tolerability data from LOGIC-2 trial of binimetinib, encorafenib with a third agent (LEE011, BKM120, BFJ398 or INC280) combination for BRAF melanoma at ECC 2015
Checkmark From LOGIC-2 trial for advanced BRAF V600 melanoma at ECC 2015
Sep 2015 - Sep 2015: From LOGIC-2 trial for advanced BRAF V600 melanoma at ECC 2015
Completed
2
158
Europe, Canada, US, RoW
LGX818, MEK162, LEE011, BGJ398, BKM120, INC280
Pfizer
Melanoma
01/23
01/23
PROPEL 2, NCT04265651 / 2019-002954-21: Study of Infigratinib in Children with Achondroplasia

Completed
2
84
Europe, Canada, US, RoW
Infigratinib 0.016 mg/kg, Infigratinib 0.032 mg/kg, Infigratinib 0.064 mg/kg, Infigratinib 0.128 mg/kg, Infigratinib 0.25 mg/kg
QED Therapeutics, Inc.
Achondroplasia
10/24
10/24
NCT06206278: Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma

Terminated
2
6
RoW
Infigratinib, BGJ398, BBP-831
LianBio LLC
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
05/24
05/24
NCT04233567: Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations

Checkmark Decision to withdraw NDA for Truseltiq which was approved for adult patients with unresectable locally advanced/metastatic 2L cholangiocarcinoma with FGFR2 fusion or other rearrangement
Oct 2022 - Oct 2022: Decision to withdraw NDA for Truseltiq which was approved for adult patients with unresectable locally advanced/metastatic 2L cholangiocarcinoma with FGFR2 fusion or other rearrangement
Checkmark Health Canada approved for the treatment of adults unresectable locally advanced or metastatic 2L cholangiocarcinoma
Sep 2021 - Sep 2021: Health Canada approved for the treatment of adults unresectable locally advanced or metastatic 2L cholangiocarcinoma
Checkmark Approved for previously-treated locally advanced or metastatic cholangiocarcinoma harboring an FGFR2 fusion or rearrangement
More
Active, not recruiting
2
17
US
Infigratinib, 3-(2,6-Dichloro-3,5-dimethoxyphenyl)-1-(6-((4-(4-ethylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)-1-methylurea, BGJ-398, BGJ398
Sameek Roychowdhury
Advanced Malignant Solid Neoplasm, Cholangiocarcinoma, Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
12/23
12/25
NCT05514912: Preoperative Nab-paclitaxel, Cisplatin, and Gemcitabine Chemotherapy With or Without Infigratinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, The OPTIC Trial

Withdrawn
2
40
NA
Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, FF 10832, FF-10832, FF10832, Gemcitabine HCI, Gemzar, LY-188011, LY188011, Infigratinib Phosphate, N'-(2,6-Dichloro-3,5-dimethoxyphenyl)-N-(6-(4-(4-ethylpiperazin-1-yl)anilino)pyrimidin-4-yl)-N-methylurea Phosphate (1:1), Truseltiq, Nab-paclitaxel, ABI 007, ABI-007, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, Nanoparticle Albumin-bound Paclitaxel, Nanoparticle Paclitaxel, Paclitaxel Albumin, paclitaxel albumin-stabilized nanoparticle formulation, Protein-bound Paclitaxel
Emory University, National Cancer Institute (NCI)
Resectable Intrahepatic Cholangiocarcinoma, Stage 0 Intrahepatic Cholangiocarcinoma AJCC v8, Stage I Intrahepatic Cholangiocarcinoma AJCC v8, Stage II Intrahepatic Cholangiocarcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8
06/27
06/27
NCT05145010 / 2021-001855-15: Extension Study of Infigratinib in Children With Achondroplasia (ACH)

Enrolling by invitation
2
300
Europe, Canada, US, RoW
Infigratinib
QED Therapeutics, Inc., QED Therapeutics, Inc.
Achondroplasia
12/31
02/32
NEWEL, NCT05222165 / 2021-005614-34: Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations

Withdrawn
1b/2
51
Europe, Canada, US
Infigratinib, BGJ398
Helsinn Healthcare SA, Labcorp Drug Development Inc
Advanced Solid Tumor, CNS Tumor, Recurrent WHO Grade II Glioma
12/22
12/22
2021-005614-34: Study of Infigratinib in Subjects with Advanced Solid and CNS Tumorsor Recurrent or Progressive Low-Grade Glioma with Selected FGFR1-3 Alterations

Not yet recruiting
1/2
51
Europe
Infigratinib hard gelatin sprinkle capsules 18 mg, Infigratinib hard gelatin sprinkle capsules 25 mg, Infigratinib hard gelatin locking capsules 75 mg, BGJ398, BBP-831, Capsule, hard, TRUSELTIQ (infigratinib hard gelatin locking capsules 25 mg), TRUSELTIQ (infigratinib hard gelatin locking capsules 100 mg)
Helsinn Healthcare SA, Helsinn Healthcare SA
Advanced solid and CNS tumors with selected FGFR1-3 mutations or fusions/rearrangements, inclusive of recurrent or progressive low-grade glioma (LGG) with selected FGFR1-3 mutations or fusions/rearrangements., Advanced solid and central nervous system tumors (brain tumors) that is coming back after treatment (recurrent) or getting worse (progressive)., Diseases [C] - Nervous System Diseases [C10]
 
 
NCT04228042: Infigratinib Before Surgery for the Treatment of Upper Tract Urothelial Cancer

Terminated
1/2
15
US
Infigratinib, 3-(2,6-Dichloro-3,5-dimethoxyphenyl)-1-(6-((4-(4-ethylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)-1-methylurea, BGJ-398, BGJ398, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Surgical Procedure, Operation, Surgery, Surgical, Surgical Intervention, Surgical Interventions, Surgical Procedures, Type of Surgery
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Renal Pelvis and Ureter Urothelial Carcinoma
04/24
04/24
NCT04424966: Infigratinib in Recurrent High-Grade Glioma Patients

Terminated
1
7
US
Infigratinib
Nader Sanai, Ivy Brain Tumor Center, Barrow Neurological Institute, QED Therapeutics
Glioma, Glioblastoma, GBM
04/23
04/23
NCT05510427: Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification

Withdrawn
1
28
NA
Infigratinib, Atezolizumab, Bevacizumab
M.D. Anderson Cancer Center, Helsinn Healthcare SA
Cholangiocarcinoma, Liver Cancer
08/23
08/23
NCT02657486: BGJ398 in Non-Muscle-Invasive Urothelial Carcinoma of the Bladder

Active, not recruiting
N/A
4
US
BGJ398
Memorial Sloan Kettering Cancer Center
Bladder Cancer, Non-Muscle-Invasive Urothelial Carcinoma
01/26
01/26
Hensify (crystalline hafnium oxide) / Nanobiotix, J&J
2021-002163-22: NBTXR3 with or without cetuximab in Locally Advanced Head & Neck Squamous Cell Carcinoma (LA-HNSCC)

Not yet recruiting
3
500
Europe, RoW
Cetuximab, [NA], [NBTXR3], Solution for infusion, Erbitux, 5 mg/mL, 20 mL vials
Nanobiotix SA, NANOBIOTIX SA, NANOBIOTIX, Nanobiotix SA
Locally Advanced Head & Neck Squamous Cell Carcinoma, The most common type of head and neck cancer is called squamous cell carcinoma coming from the membrane lining the mouth, and the parts of the digestive and respiratory tubes of the neck., Diseases [C] - Cancer [C04]
 
 
NANORAY-312, NCT04892173 / 2021-002163-22: JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

Recruiting
3
500
Europe, Japan, US, RoW
JNJ-90301900 (NBTXR3), Functionalized hafnium oxide nanoparticles, NBTXR3, Cetuximab, Erbitux, Radiation Therapy
Johnson & Johnson Enterprise Innovation Inc., Nanobiotix SA
Locally Advanced Head and Neck Squamous Cell Carcinoma, Aged
06/26
06/27
CONVERGE, NCT06667908: A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

Recruiting
2
130
US, RoW
JNJ-90301900, Durvalumab, Concurrent Chemo/Radiation Therapy (cCRT), Concurrent Chemo/Radiation Therapy (cCRT): Carboplatin, Concurrent Chemo/Radiation Therapy (cCRT): Paclitaxel
Johnson & Johnson Enterprise Innovation Inc.
Carcinoma, Non-Small-Cell Lung
12/28
12/28
NCT04862455: NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Cancer

Active, not recruiting
2
14
US
Hafnium Oxide-containing Nanoparticles NBTXR3, NBTXR3, Hypofractionated Radiation Therapy, Hypofractionated Radiotherapy, hypofractionation, Radiation, Hypofractionated, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Stereotactic Body Radiation Therapy, SABR, SBRT, Stereotactic Ablative Body Radiation Therapy
M.D. Anderson Cancer Center
Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
09/26
09/26
NCT05039632: Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies

Recruiting
1/2
40
US
Hafnium Oxide-containing Nanoparticles NBTXR3, NBTXR3, Radiation Therapy, Cancer Radiotherapy, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Liver, Metastatic Malignant Neoplasm in the Lung, Metastatic Malignant Solid Neoplasm
02/26
02/26
NBTXR3-102, NCT01946867: NBTXR3 and Radiation Therapy in Treating Patients With Locally Advanced SCC of the Oral Cavity or Oropharynx

Active, not recruiting
1
75
Europe
NBTXR3 activated by IMRT
Nanobiotix
Head and Neck Cancer
02/23
02/23
Study 1100, NCT03589339: NBTXR3 Activated by Radiotherapy for Patients with Advanced Cancers Treated with an Anti-PD-1 Therapy

Recruiting
1
145
US
NBTXR3, SABR, Stereotaxic Ablative Radiotherapy, Stereotaxic Body Radiation Therapy, Nivolumab, Opdivo, Pembrolizumab, Keytruda
Nanobiotix
Radiotherapy, Immunotherapy, Microsatellite Instability-High Solid Malignant Tumour, Metastasis from Malignant Tumor of Liver, Squamous Cell Carcinoma of Head and Neck, Metastasis from Malignant Tumor of Cervix, Metastatic Renal Cell Carcinoma, Metastasis from Malignant Melanoma of Skin (disorder), Metastatic Triple-Negative Breast Carcinoma, Metastatic NSCLC, Metastasis from Malignant Tumor of Bladder (Disorder)
04/27
05/28
NCT04505267: NBTXR3 and Radiation Therapy for the Treatment of Inoperable Recurrent Non-small Cell Lung Cancer

Recruiting
1
24
US
Hafnium Oxide-containing Nanoparticles NBTXR3, NBTXR3, Radiation Therapy, Cancer Radiotherapy, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Recurrent Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma
03/26
03/26
NCT04615013: NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer

Recruiting
1
24
US
Capecitabine, Ro 09-1978/000, Xeloda, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Docetaxel, Docecad, RP56976, Taxotere, Taxotere Injection Concentrate, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Hafnium Oxide-containing Nanoparticles NBTXR3, NBTXR3, Intensity-Modulated Radiation Therapy, IMRT, Intensity Modulated RT, Intensity-Modulated Radiotherapy, Radiation, Intensity-Modulated Radiotherapy, Leucovorin, Folinic acid, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Cervical Esophagus Adenocarcinoma, Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Gastroesophageal Junction Adenocarcinoma, Pathologic Stage II Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage III Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8, Thoracic Esophagus Adenocarcinoma
10/25
10/25
NCI-2020-03731, NCT04484909: NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer

Recruiting
1
24
US
Hafnium Oxide-containing Nanoparticles NBTXR3, NBTXR3, Radiation Therapy, Cancer Radiotherapy, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8
12/26
12/26
Camzyos (mavacamten) / BMS
NCT07004972: A Study of Mavacamten in Adults With Obstructive Hypertrophic Cardiomyopathy in India (ROVER)

Not yet recruiting
4
50
RoW
Mavacamten, BMS-986427
Bristol-Myers Squibb
Symptomatic Obstructive Hypertrophic Cardiomyopathy
12/27
12/27
MEMENTO, NCT06112743: A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Recruiting
4
85
Europe, Canada, US, RoW
Mavacamten
Bristol-Myers Squibb
Cardiomyopathy, Hypertrophic
09/26
09/26
VALOR-HCM, NCT04349072: A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy

Completed
3
112
US
Mavacamten, Placebo
Bristol-Myers Squibb
HOCM, Hypertrophic Obstructive Cardiomyopathy
02/22
05/24
2021-005329-26: A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with Cardiomyopathy

Ongoing
3
420
Europe
Mavacamten, MYK-461, Capsule, hard
Myokardia, Inc., Myokardia, Inc.
Symptomatic Nonobstructive Hypertrophic Cardiomyopathy, Symptomatic hardening of the left ventricle., Diseases [C] - Cardiovascular Diseases [C14]
 
 
EXPLORER-CN, NCT05174416: A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCM

Completed
3
81
RoW
Mavacamten, MYK-461, BMS-986327, Placebo
LianBio LLC
Obstructive Hypertrophic Cardiomyopathy
03/23
07/24
HORIZON-HCM, NCT05414175: A Study of Mavacamten in Obstructive Hypertrophic Cardiomyopathy

Active, not recruiting
3
38
Japan
Mavacamten, BMS-986427, MYK-461
Bristol-Myers Squibb
Cardiomyopathy, Hypertrophic Obstructive
11/23
03/26
SCOUT-HCM, NCT06253221: A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Active, not recruiting
3
40
Europe, Canada, US, RoW
Mavacamten, BMS-986427, Placebo
Bristol-Myers Squibb
Cardiomyopathy, Hypertrophic
02/28
03/31
ODYSSEY_HCM, NCT05582395 / 2021-005329-26: A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy

Active, not recruiting
3
580
Europe, Canada, Japan, US, RoW
Mavacamten, BMS-986427, MYK-461, Placebo
Bristol-Myers Squibb
Cardiomyopathy, Hypertrophic
03/25
06/29
NCT03723655 / 2018-004039-64: A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM

Active, not recruiting
2/3
282
Europe, US, RoW
mavacamten, MYK-461
Bristol-Myers Squibb
Hypertrophic Cardiomyopathy, Obstructive Hypertrophic Cardiomyopathy, Non-obstructive Hypertrophic Cardiomyopathy
01/26
01/26
PIONEER-OLE, NCT03496168: Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in PIONEER

Completed
2
13
US
mavacamten, MYK-461
Bristol-Myers Squibb
Hypertrophic Cardiomyopathy
11/23
11/23
EMBARK-HFpEF, NCT04766892: A Study of Mavacamten in Participants With HFpEF and Elevation of NT-proBNP With or Without Elevation of cTnT

Completed
2
30
Canada, US
mavacamten
Bristol-Myers Squibb
Heart Failure With Preserved Ejection Fraction
02/24
02/24
NCT05658146: A Study to Assess the Effects on the Single-Dose Drug Levels of Mavacamten in Healthy Participants

Completed
1
95
US
Mavacamten Capsule 1, BMS-986427, MYK-461, Mavacamten Capsule 2, Mavacamten Capsule 3
Bristol-Myers Squibb
Healthy Participants
07/23
07/23
NCT05719805: A Study to Evaluate the Effects of Mavacamten in Healthy Participants

Completed
1
84
US
Mavacamten, MYK-461
Bristol-Myers Squibb
Healthy Participants
07/23
07/23
NCT06211179: A Study to Assess the Relative Bioavailability of 5 mg Mavacamten Opened Capsule Administered Via Nasogastric Tube Compared to Intact Oral 5 mg Mavacamten in Healthy Participants

Completed
1
34
US
Treatment A: Mavacamten intact oral capsule, Treatment B: Mavacamten open capsule in suspension, Treatment C: Mavacamten open capsule in suspension administered via nasogastric tube (NGT)
Bristol-Myers Squibb
Healthy Volunteers
06/24
06/24
COLLIGO-HCM, NCT06372457: A Multinational Observational Study of the Real-World Effectiveness of Mavacamten Among Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

Active, not recruiting
N/A
500
US
Approved Hypertrophic Cardiomyopathy drug treatments, Mavacamten
Bristol-Myers Squibb
Hypertrophic Cardiomyopathy (HCM)
03/25
06/25
NCT06549608: A Retrospective Cohort Study of Mavacamten Patient Support Program in Canada

Active, not recruiting
N/A
685
Canada
Mavacamten
Bristol-Myers Squibb
Hypertrophic Cardiomyopathy
05/24
04/25
COMPASS-HCM, NCT06551129: Real-world Patient Reported Outcomes Among Patients Treated With Camzyos

Recruiting
N/A
118
US
Mavacamten
Bristol-Myers Squibb
Obstructive Hypertrophic Cardiomyopathy
12/26
06/27
MAVEN, NCT06338202: Real-World Effectiveness of Mavacamten in Canada

Recruiting
N/A
100
Canada
Mavacamten
Bristol-Myers Squibb
Obstructive Hypertrophic Cardiomyopathy (oHCM)
11/24
11/24
NCT06146660: A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Recruiting
N/A
600
RoW
Mavacamten
Bristol-Myers Squibb
Obstructive Hypertrophic Cardiomyopathy
11/26
11/26
NCT06856265: Efficacy of Mavacamten Combined With Radiofrequency Ablation in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Not yet recruiting
N/A
40
NA
radiofrequency ablation, Mavacamten
Shanghai Chest Hospital
Obstructive Hypertrophic Cardiomyopathy, Mavacamten, Radiofrequency Ablation
12/25
12/25
NCT06947590: Efficacy of Mavacamten in Patients With Symptomatic Latent Obstructive Hypertrophic Cardiomyopathy

Active, not recruiting
N/A
78
RoW
mavacamten
Xu Liu
HCM - Hypertrophic Cardiomyopathy, Mavacamten
02/26
02/26
MavaPET, NCT06023186: Effect of Mavacamten Treatment on Coronary Flow Reserve in oHCM

Recruiting
N/A
20
US
mavacamten, Camzyos
Michael Ayers, Bristol-Myers Squibb
Obstructive Hypertrophic Cardiomyopathy
08/26
09/26
NCT05939700: Mavacamten Pregnancy Surveillance Program

Recruiting
N/A
20
US
Mavacamten
Bristol-Myers Squibb
Breastfeeding, Hypertrophic Cardiomyopathy, Pregnancy Related
04/27
04/27
DISCOVER-HCM, NCT05489705: A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)

Recruiting
N/A
1600
Europe, US
Mavacamten, Non-mavacamten symptomatic oHCM therapy
Bristol-Myers Squibb
Obstructive Hypertrophic Cardiomyopathy
08/29
08/29
omilancor (BT-11) / LianBio, NImmune Biopharma
ACTRN12618001210268: A Randomized, Placebo-Controlled, Sequential Single and Multiple Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral BT-11 in Healthy Adult Male and Female Volunteers

Recruiting
1
70
 
Landos Biopharma Australia Pty Ltd, Landos Biopharma Australia Pty. Ltd.
Inflammatory Bowel Disease, Ulcerative colitis, Crohn's Disease
 
 
sisunatovir (PF-07923568) / LianBio
NCT06079320: A Study to Learn About the Study Medicine Sisunatovir in Adults With Respiratory Syncytial Virus (RSV) Infection

Terminated
2/3
16
Japan, US, RoW
Sisunatovir, Placebo
Pfizer
Respiratory Syncytial Virus Infection
09/24
09/24
2017-001282-24: A clinical trial of RV521 in healthy volunteers

Not yet recruiting
2
66
Europe
RV521 50mg, RV521 100mg, RV521, 200mg, RV521, Capsule
ReViral Ltd, ReViral Ltd
Respiratory Syncytial Virus Infection, RSV is a common virus that can cause severe chest infections in small children, adults with heart, lung and immune system conditions and elderly people., Diseases [C] - Virus Diseases [C02]
 
 
2019-003746-33: Study of RV521 for the treatment of adults who have received a blood cell transplant and that have a respiratory infection caused by the virus RSV

Not yet recruiting
2
200
Europe
RV521, Capsule
ReViral Ltd., ReViral
Symptomatic RSV infection (upper airway involvement only) in subjects who have undergone HCT transplantation within 1 year of Randomization and who are moderately to severely immunocompromised., respiratory infection, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
REVIRAL 1, NCT04225897: A Study to Learn About the Effects of Sisunatovir in Infants With Respiratory Syncytial Virus Lower Respiratory Tract Infection.

Terminated
2
51
Europe, Canada, RoW
RV521, sisunatovir, Placebo
Pfizer
Respiratory Syncytial Virus (RSV), Lower Resp Tract Infection
12/22
12/22
2018-001010-15: A phase 2a Study in Infants with RSV lower respiratory tract infection, to evaluate the safety, tolerability, pharmacokinetics and antiviral effect of RV521.

Not yet recruiting
2
184
Europe
Sisunatovir, RV521, Powder for oral solution
ReViral Ltd., ReViral Ltd.
Respiratory Syncytial Virus Infection, Respiratory Syncytial Virus Infection, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
NCT05873764: A Study to Learn About Effect of Sisunatovir in Healthy Adult Male Participants

Completed
1
9
US
200 mg RV521/78 µCi [ 14C]-RV521.
Pfizer
Respiratory Syncytial Virus Infections
07/22
07/22
NCT05712460: A Study to Assess the Safety, Effects and Palatability of Sisunatovir in Healthy Adult Participants

Completed
1
12
Europe
sisunatovir, Placebo
Pfizer
Respiratory Syncytial Viruses
04/23
04/23
NCT06003829: A Study to Learn About the Tastes of Different Suspensions With the Study Medicine (PF-07923568) in Healthy Adult Participants.

Completed
1
12
Europe
Sinsunatovir, Bitrex
Pfizer
Healthy
09/23
09/23
NCT05878522: A Study to Investigate the Effects of Sisunatovir on QTc Interval in Healthy Adult Participants.

Completed
1
43
US
sisunatovir, PF-07923568, placebo, moxifloxacin
Pfizer
Healthy
10/23
10/23
NCT05994963: A Study to Compare Different Preparations of Sisunatovir in Healthy Adult Participants.

Completed
1
25
Europe
sisunatovir, PF-07923568, RV521
Pfizer
Healthy
02/24
02/24
NCT05857644: A Study to Compare How the Study Medicine (PF-07923568) is Processed in Participants With Different Levels of Loss of Liver Function to Healthy Participants.

Completed
1
28
US
PF-07923568, Sisunatovir
Pfizer
Liver Diseases, Hepatic Impairment
02/24
02/24
NCT06105983: A Study to Learn How a Medicine That Reduces Stomach Acid Affects the Level of Sisunatovir in the Blood of Healthy Adults.

Completed
1
40
Europe
Sisunatovir, Rabeprazole 40 mg, Sisunatovir suspension, Rabeprazole 20 mg
Pfizer
Healthy
07/24
07/24
NCT05987072: A Study to Learn How the Study Medicine Called Sisunatovir is Tolerated and Acts in the Bodies of Chinese Healthy Adults.

Completed
1
12
RoW
Sisunatovir
Pfizer
Respiratory Syncytial Virus Infection
12/23
12/23
NCT06037031: A Study to Learn How the Body Processes the Study Medicine Called PF-07923568 in People With Loss of Kidney Function

Completed
1
16
US
Drug: PF-07923568, Sisunatovir
Pfizer
Renal Impairment
07/24
07/24
NCT06102174: A Study to Learn About the Amount of the Study Medicine (Sisunatovir) in Blood and Its Safety in Infants and Children With Pneumonia Caused by RSV

Terminated
1
10
Japan, US, RoW
Placebo, Active, PF-07923568, RV521
Pfizer
Respiratory Syncytial Virus Infections
09/24
09/24
amelenodor (ABBV-113) / AbbVie
NCT05785715: Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis

Hourglass Oct 2024 - Dec 2024 : Topline data from trial for moderate to severe ulcerative colitis
Terminated
2
81
Europe, US
NX-13 250mg, NX-13 750mg, NX-13 Placebo
AbbVie
Ulcerative Colitis
05/25
05/25
Xdemvy (lotilaner ophthalmic) / Tarsus Pharma
Ariel, NCT06182358: Impact of XDEMVY® on Demodex Blepharitis in Soft Contact Lens Wearers

Completed
4
145
US
Lotilaner ophthalmic solution, 0.25%, Vehicle control
Tarsus Pharmaceuticals, Inc.
Demodex Blepharitis
01/25
01/25
NCT05629390: Trial to Evaluate the Efficacy and Safety of TP-03, LIBRA Study

Completed
3
163
RoW
Lotilaner, TP-03, S-Misoxam, Vehicle Control
LianBio LLC
Blepharitis
09/23
04/24
Ersa, NCT05454956: Pilot Study Comparing the Safety and Efficacy of Two Dosing Regimens of TP-03 for the Treatment of MGD

Completed
2
40
US
TP-03, TP-03 Vehicle
Tarsus Pharmaceuticals, Inc.
Meibomian Gland Dysfunction, Blepharitis, Demodex Infestation
05/23
05/23
Rhea, NCT06054217: Effect of an Exploratory Vehicle on Meibomian Gland Dysfunction in Patients With Demodex

Active, not recruiting
2
36
US
Vehicle of TP-03, Exploratory Vehicle
Tarsus Pharmaceuticals, Inc.
Meibomian Gland Dysfunction, Demodex Infestation of Eyelid, Blepharitis, Demodectic Blepharitis
06/24
06/24
NCT05138861: A Six Week Pharmacokinetic Study of TP-03 in Healthy Subjects

Completed
1
24
Canada
TP-03 (Lotilaner Ophthalmic Solution), 0.25%
Tarsus Pharmaceuticals, Inc.
Healthy
09/21
09/21
BMS-986466 / BMS
NCT06024174: A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors

Terminated
1/2
5
Europe, US, RoW
BMS-986466, BBP-398, IACS-15509, Adagrasib, MRTX849, KRAZATI®, Cetuximab, Erbitux®
Bristol-Myers Squibb
Advanced Solid Tumors
05/24
05/24
NCT04528836: First-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients With Advanced Solid Tumors

Terminated
1
72
US
BBP-398 (Formerly known as IACS-15509)
Navire Pharma Inc., a BridgeBio company
Tumor, Solid
03/24
07/24
NCT05621525: Phase I Study of the BBP-398 in Patients With Advance Solid Tumors

Terminated
1
7
RoW
BBP-398, IACS-15509
LianBio LLC
Advanced Solid Tumor, Advanced or Metastatic Non-small Cell Lung Cancer
03/24
03/24
Argonaut, NCT05480865: SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation

Terminated
1
28
Europe, RoW
BBP-398, sotorasib
Navire Pharma Inc., a BridgeBio company, Amgen
Solid Tumor, Adult, Metastatic Solid Tumor, Metastatic NSCLC, Non Small Cell Lung Cancer
08/24
08/24
NCT05375084: SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation

Terminated
1
21
US
BBP-398 with nivolumab
Navire Pharma Inc., a BridgeBio company, Bristol-Myers Squibb
Non Small Cell Lung Cancer, Solid Tumor
04/24
07/24
NCT06032936: BBP-398 in Combination With Osimertinib in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutations

Terminated
1
4
RoW
BBP-398, IACS-15509, osimertinib
LianBio LLC
NSCLC
03/24
03/24

Download Options